The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,458,322 reports of adverse events following COVID-19 vaccines were submitted between Dec. 14, 2020, and Nov. 4, 2022, to the Vaccine Adverse Event Reporting System (VAERS).

VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 31,961 reports of deaths and 265,274 serious injuries, including deaths, during the same time period.

There were a total of 7,783 reports of adverse events following the new COVID-19 bivalent booster as of Nov. 4, 2022, with 45% attributed to Moderna’s booster and 55% attributed to Pfizer/BioNTech’s booster. The data included a total of 61 deaths and 434 serious injuries.

As of Nov. 10, 31.4 million people have received the updated bivalent booster dose.

Of the 31,961 reported deaths, 20,381 cases are attributed to Pfizer’s COVID-19 vaccine, 8,696 cases to Moderna, 2,773 cases to Johnson & Johnson (J&J) and no cases yet reported for Novavax.

Excluding “foreign reports” to VAERS, 894,850 adverse events, including 15,096 deaths and 93,362 serious injuries, were reported in the U.S. between Dec. 14, 2020, and Nov. 4, 2022.

Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.

Of the 15,096 deaths reported as of Nov. 4, 7% occurred within 24 hours of vaccination and 15% occurred within 48 hours of vaccination.

In the U.S., 640 million COVID-19 vaccine doses had been administered as of Nov. 2, including 381 million doses of Pfizer, 241 million doses of Moderna and 19 million doses of J&J.

vaers data vaccine injury 11-14-22

Every Friday, VAERS publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed. Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.

VAERS data from Dec. 14, 2020, to Nov. 4, 2022, for 6-month-olds to 5-year-olds show:

  • 5 reports of myocarditis and pericarditis (heart inflammation).

The CDC uses a narrowed case definition of “myocarditis,” which excludes cases of cardiac arrest, ischemic strokes and deaths due to heart problems that occur before one has the chance to go to the emergency department.

VAERS data from Dec. 14, 2020, to Nov. 4, 2022, for 5- to 11-year-olds show:

The latest death reported in this age group was that of a 10-year-old boy who died suddenly six days after receiving a third dose of Moderna’s COVID-19 vaccine. According to the report, “It is unknown if an autopsy was performed.”

According to the company (Moderna) comment included in the report, “Cause of death was reported as cardiorespiratory arrest. Information regarding clinical evaluation, diagnostic tests, treatment provided, or autopsy reports has not been disclosed.”

VAERS data from Dec. 14, 2020, to Nov. 4, 2022, for 12- to 17-year-olds show:

According to the CDC, “VAERS data available to the public include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.”

  • 269 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death.
  • 27 cases of postural orthostatic tachycardia syndrome (POTS) with all cases attributed to Pfizer’s vaccine.

VAERS data from Dec. 14, 2020, to Nov. 4, 2022, for all age groups combined, show:

Children’s Health Defense (CHD) asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following these three steps.

Pfizer, Moderna developing combined mRNA Omicron-flu vaccine

Pfizer and Moderna are developing a combination COVID-19 and flu injection utilizing mRNA coding for the BA4/BA5 Omicron subvariant and new mRNA coding for antigens contained in the influenza virus.

Because the COVID-19 component, which is under Emergency Use Authorization (EUA), has failed in animal studies and no human trials have been reported, that component should be off the table from the start, according to Dr. Peter A. McCullough.

Combining the genetic code for both the SARS-CoV-2 spike protein and conserved proteins of influenza A and B would mean installation of the long-lasting genetic code for multiple foreign proteins in the human body.

Production of these proteins will induce an ongoing multi-pronged immune response that could create amplified side effects. mRNA coding for influenza would be a new biological product not under EUA and should have to go through the full five-year regulatory development cycle for genetic biologicals.

However, it looks like vaccine companies are trying the shortcut this development cycle by combining the non-emergency flu shot with the EUA COVID-19 vaccine.

Pfizer press release on new bivalent booster raises questions

On Nov. 4, Pfizer announced what some media outlets called “good news” about its COVID-19 bivalent booster, for which the FDA in August granted EUA on the basis of testing conducted on eight mice.

In a press release, Pfizer summarized the updated data from its phase 2/3 clinical trial on the Pfizer-BioNTech Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.

In simplest terms, the bivalent booster increased antibodies to the Omicron sublineages by a factor of 13.2, whereas the original booster increased them by a factor of only 2.9. The increase was seen only in people over age 55.

Although the new booster produced a more modest increase (9.5 fold) in antibodies in the younger age group (18-55), Pfizer chose not to report what the response was in the age-matched group who received the original booster.

Pfizer provided no comparative results in the 18-55 group and no clinical outcome differences in terms of COVID-19 infections — either in the Nov. 4 press release or in a previous Pfizer press release summarizing preliminary data.

At what point does an “increase in the neutralizing antibody response” confer “stronger protection?”

Neither BioNTech, who co-produced the Pfizer/BioNTech COVID-19 vaccine, nor the FDA knows — despite insisting the agency has enough grounds to cajole/compel/coerce those who acquired SARS-CoV-2 antibodies from a previous bout with COVID-19 to get jabbed anyway.

Rutgers announces COVID vaccine trial with Pfizer, as CHD lawsuit against Rutgers advances

CHD on Nov. 7, filed a summary of its appeal in a lawsuit against Rutgers University over the university’s COVID-19 vaccine mandate.

The attorney representing CHD and 13 Rutgers University students in the lawsuit said the District Court of New Jersey didn’t follow the legal standard when it dismissed CHD’s case.

In an interview this week with The Defender, Julio C. Gomez of Gomez LLC, lead counsel in the case, said U.S. District Judge Zahid N. Quraishi’s argument for granting the university’s motion to dismiss “failed to accept the facts as alleged in the plaintiffs’ complaint as true,” as required under the legal standard on a motion to dismiss.

CHD on Oct. 19 appealed the decision and on Nov. 7 filed a summary of its appeal.

Gomez also spoke with The Defender about Rutgers’ Nov. 4 announcement that it is partnering with Pfizer on a new clinical trial to evaluate the safety and efficacy of the bivalent COVID-19 vaccine in children under age 5.

The new clinical trial is the latest evidence of Rutgers’ conflicts of interest related to its COVID-19 vaccine policies, Gomez said.